Sunday, June 23, 2019 11:38:51 AM
Xena:If genes affecting ABC are involved then we might get good results with A and incomplete results with B&C but still exceed SOC en toto
You are of course describing the (a) learning process. We all understand it is iterative. Many ways to describe what happens during discovery. The dilemma in the CNS space has been the regulatory bodies processes somehow truncated the entire point of this concept. That is the most generous description I can come up with for how the Amyloid thesis went on for 30+ years and hundreds of trials and/1000's of dead trial participants. Not to beat a dead hose but that failure rate was the indicator that the process was going no where and to STOP.
What we have with Anavex is an opportunity to do the CNS disease problem solving process correctly, if we are allowed to. Dr.G. stopped the carnage by stopping the Amyloid thesis (IMO) b/c he could see nothing being learned. It had to be done. Sad to say the same structure for trials is more or less still in place. It has to be taken apart of redesigned b/c it is fundamentally incompatible w/learning and there is a limit to how many "stove pipe" processes that can be done/afforded at any time. It is a self limiting construct.
I like the Dr. Senge's model of learning and see that A2-73 trials are now at level 2. We are in a position to begin to understand what we know we do not know.(YET) It is at this interface that learning occurs. If somehow the use of new tools and technology can be applied (either in sequence or concurrently) then a vast number of simultaneous breakthroughs is possible (flashover). A2-73 trails might be seen as a true catalyst in the space if allowed. Trial data that describes a treated patients responses to light or sound or other stimulus (measured in pico secs) or may be extrapolated to changes in patient cognition which can be monitored (and learned from) w/precision. This type of learning will then trigger other new ideas and WHAMM ...learning happens. This is my opinion of what I think we are on the brink of doing here.
This is process (or should be) all about learning. W/O A2-73 and a few good people in the right places in time it will not happen. What a shame if we let this go by again. If not US Then WHO? If Not now then When? Lead, follow or get out of the way. ...I'll think of a few more for Monday's post.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
